Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia
NCT ID: NCT01027624
Last Updated: 2011-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3000 participants
OBSERVATIONAL
2009-11-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pan-European Survey on the Under Treatment of Hypercholesterolemia
NCT00542867
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
NCT01025388
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
NCT01604733
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
NCT01031277
National Survey on Dyslipidemic Patients
NCT00701402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyperchlesterolaemia
Participants undertreated with hypercholesterolaemia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must provide informed consent and comply with the survey procedures.
* Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals Pty Ltd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof F Raal
Role: PRINCIPAL_INVESTIGATOR
National Co-ordinator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Johannesburg, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CZA-DUM-2009/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.